Laura Waters

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 194 citations · Full text

Medicine, Oncology, Pharmacology +10

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers

Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski et al. · Journal of Medicinal Chemistry · 2022 · 151 citations · Full text

Pharmacy, Oncology, Pharmacology +15

BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022

Laura Waters, Alan Winston, Iain Reeves et al. · HIV Medicine · 2022 · 85 citations · Full text

Public Health, Infectious Disease Control, Pharmacotherapy +17

Hepatitis C Virus Infection in HIV Type 1--Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events

Justin Stebbing, Laura Waters, S Mandalia et al. · Clinical Infectious Diseases · 2005 · 41 citations

Life Sciences, Immunology, Infectious Diseases +17

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos et al. · Molecular Cancer Therapeutics · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +14